Propanc Biopharma Inc [NASDAQ: PPCB] stock went on an upward path that rose over 103.83% on Monday, amounting to a one-week price decrease of less than -35.00%.
Over the last 12 months, PPCB stock dropped by -51.25%. The one-year Propanc Biopharma Inc stock forecast points to a potential upside of 98.46.
The market cap for the stock reached $67.94 million, with 11.61 million shares outstanding and 11.60 million shares in the current float. Compared to the average trading volume of 13.57K shares, PPCB stock reached a trading volume of 67796062 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Propanc Biopharma Inc [PPCB]:
The Price to Book ratio for the last quarter was 3.75, with the Price to Cash per share for the same quarter was set at 0.00.
PPCB Stock Performance Analysis:
Propanc Biopharma Inc [PPCB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -35.00. With this latest performance, PPCB shares dropped by -2.50% in over the last four-week period, additionally sinking by -67.50% over the last 6 months – not to mention a drop of -51.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PPCB stock in for the last two-week period is set at 48.46, with the RSI for the last a single of trading hit 3.82, and the three-weeks RSI is set at 2.79 for Propanc Biopharma Inc [PPCB]. The present Moving Average for the last 50 days of trading for this stock 5.39, while it was recorded at 6.67 for the last single week of trading, and 13.53 for the last 200 days.
Propanc Biopharma Inc (PPCB) Capital Structure & Debt Analysis
According to recent financial data for Propanc Biopharma Inc. ( PPCB), the Return on Equity (ROE) stands at -767.20%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -489.35%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Propanc Biopharma Inc’s Return on Invested Capital (ROIC) is -303.58%, showcasing its effectiveness in deploying capital for earnings.
Propanc Biopharma Inc (PPCB) Efficiency & Liquidity Metrics
Based on Propanc Biopharma Inc’s (PPCB) latest financial statements, the Debt-to-Equity Ratio is 0.07%, indicating its reliance on debt financing relative to shareholder equity.
Propanc Biopharma Inc (PPCB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Propanc Biopharma Inc. (PPCB) effectively leverages its workforce, generating an average of -$27605000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.24% and a Quick Ratio of 2.24%, indicating strong ability to cover short-term liabilities.
Propanc Biopharma Inc [PPCB] Institutonal Ownership Details
There are presently around $7.75%, or 27.17%% of PPCB stock, in the hands of institutional investors.
